Back to Search Start Over

Population Pharmacokinetics of Doxycycline in Children

Authors :
Elizabeth J. Thompson
Stephen J. Balevic
Kira M Clark
Barrie Harper
Rohit Kalra
Janice E. Sullivan
Elizabeth H Payne
Matthew M. Laughon
Susan R. Mendley
Jinson Erinjeri
Christoph P. Hornik
Casey E Gelber
Huali Wu
Chiara Melloni
Michael Cohen-Wolkowiez
Source :
Antimicrob Agents Chemother
Publication Year :
2019
Publisher :
American Society for Microbiology, 2019.

Abstract

Doxycycline is a tetracycline-class antimicrobial labeled by the U.S. Food and Drug Administration for children >8 years of age for many common childhood infections. Doxycycline is not labeled for children ≤8 years of age, due to the association between tetracycline-class antibiotics and tooth staining, although doxycycline may be used off-label under severe conditions. Accordingly, there is a paucity of pharmacokinetic (PK) data to guide dosing in children 8 years and younger. We leveraged opportunistically collected plasma samples after intravenous (i.v.) and oral doxycycline doses received per standard of care to characterize the PK of doxycycline in children of different ages and evaluated the effect of obesity and fasting status on PK parameters. We developed a population PK model of doxycycline using data collected from 47 patients 0 to 18 years of age, including 14 participants ≤8 years. We developed a 1-compartment PK model and found doxycycline clearance to be 3.32 liters/h/70 kg of body weight and volume to be 96.8 liters/70 kg for all patients, comparable to values reported in adults. We estimated a bioavailability of 89.6%, also consistent with adult data. Allometrically scaled clearance and volume of distribution did not differ between children 2 to ≤8 years of age and children >8 to ≤18 years of age, suggesting that younger children may be given the same per-kilogram dosing. Obesity status and fasting status were not selected for inclusion in the final model. Additional doxycycline PK samples collected in future studies may be used to improve model performance and maximize its clinical value.

Details

ISSN :
10986596 and 00664804
Volume :
63
Database :
OpenAIRE
Journal :
Antimicrobial Agents and Chemotherapy
Accession number :
edsair.doi.dedup.....6601a5a3f090e8727c071a28144bab87
Full Text :
https://doi.org/10.1128/aac.01508-19